Rezolute, Inc. develops therapies for rare and metabolic diseases, with recent company updates centered on hypoglycemia caused by hyperinsulinism. Its principal news themes include ersodetug, the Phase 3 sunRIZE study in congenital hyperinsulinism, the Phase 3 upLIFT study in tumor hyperinsulinism, and clinical evidence from continuous glucose monitoring, biomarker analyses and expanded access experience.
Rezolute news also covers FDA interactions, presentations at pediatric endocrinology and life sciences meetings, quarterly financial results, business updates and investor conference participation. The company’s updates generally connect clinical-program progress with regulatory engagement, cash resources and development priorities for its hyperinsulinism pipeline.
Rezolute (Nasdaq: RZLT) reported first quarter fiscal 2026 results and a business update for the quarter ended September 30, 2025. The company said it remains on track to report topline Phase 3 sunRIZE results in December 2025 and that the FDA has aligned that sunRIZE meets registrational requirements for a BLA filing. For tumor hyperinsulinism, Rezolute said it achieved FDA alignment on a streamlined single-arm Phase 3 upLIFT study with enrollment underway and topline data expected in the second half of 2026. Financials: cash and investments were $152.2M at September 30, 2025; R&D expense was $13.1M; G&A was $6.7M; net loss was $18.2M.
Rezolute (Nasdaq: RZLT) will host a virtual investor event on Monday, November 10, 2025 from 12:00–1:30 pm EST to review the clinical development and market opportunity for ersodetug.
Management will discuss two Phase 3 programs: the sunRIZE study in congenital hyperinsulinism with topline results expected in December 2025, and the upLIFT study in tumor hyperinsulinism. The program discussion will include anticipated commercial opportunities and remarks from hyperinsulinism experts Mansa Krishnamurthy, MD, and Azeez Farooki, MD.
Investors can join via phone or the live webcast on Rezolute’s investor site; a replay will be available about two hours after the event.
Rezolute (Nasdaq: RZLT) announced management will participate in three investor conferences in late 2025: the Maxim Growth Summit on October 22-23, 2025, the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10-12, 2025, and the Jefferies London Healthcare Conference on November 17-20, 2025.
Management expects to hold one-on-one investor meetings during the events. Investors who want to schedule meetings are instructed to contact their Maxim, Guggenheim, or Jefferies representative.
Rezolute (NASDAQ: RZLT) announced an inducement equity grant under Nasdaq Listing Rule 5635(c)(4) made as of September 30, 2025. The company granted options to purchase a total of 125,000 shares of common stock to two new employees.
The options carry a 10-year term, an exercise price of $9.40 per share (the closing price on September 30, 2025), and vest over four years subject to continued service. The awards were approved by the Compensation Committee as a material inducement to accept employment.
Rezolute (Nasdaq: RZLT) reported its Q4 and FY2025 financial results, highlighting significant progress in its hyperinsulinism treatment programs. The company completed enrollment for its Phase 3 sunRIZE trial with 62 participants for congenital hyperinsulinism (HI), with topline results expected in December 2025. Additionally, Rezolute secured FDA alignment for a streamlined Phase 3 upLIFT study for tumor HI, requiring only 16 participants.
Financial highlights include cash position of $167.9M as of June 30, 2025, up from $127.1M year-over-year. R&D expenses increased to $61.5M for FY2025, while net loss widened to $74.4M. The company strengthened its leadership team with the appointment of Dr. Sunil Karnawat as Chief Commercial Officer, bringing extensive rare disease commercialization experience.
Rezolute (NASDAQ:RZLT) has secured FDA alignment for a streamlined Phase 3 trial design of ersodetug in tumor hyperinsulinism (HI). The agency approved significant modifications to the upLIFT study, eliminating the need for a double-blind placebo-controlled trial and reducing the required participants to as few as 16 patients.
The study will now proceed as a single-arm open-label trial, with patient recruitment ongoing in the U.S. and Europe. The FDA will consider Rezolute's pivotal sunRIZE trial in congenital HI as confirmatory evidence, acknowledging ersodetug's broader applicability. Topline data is expected in the second half of 2026, while the sunRIZE trial results are anticipated in December 2025.
Rezolute (Nasdaq: RZLT), a late-stage rare disease company specializing in hypoglycemia treatment caused by hyperinsulinism, has announced its participation in three major upcoming investor conferences in September 2025.
The company will attend the Cantor Global Healthcare Conference (September 3-5), the H.C. Wainwright Global Investment Conference (September 8-10), and the Morgan Stanley Global Healthcare Conference (September 8-10). Management will engage in Fireside Chats and one-on-one meetings with investors during these events.
Rezolute (NASDAQ:RZLT), a late-stage rare disease company, has appointed Sunil Karnawat as Chief Commercial Officer effective August 18, 2025. Karnawat brings over 25 years of experience in global commercialization of biopharmaceuticals and medical devices, including successful launches of four ultra-rare disease products at Ultragenyx.
The appointment comes as Rezolute advances ersodetug through Phase 3 studies for both congenital and tumor hyperinsulinism. As part of his compensation package, Karnawat received an inducement stock option grant of 275,000 shares at $6.55 per share, with a four-year vesting schedule.
Rezolute (NASDAQ:RZLT), a late-stage rare disease company specializing in hypoglycemia treatment caused by hyperinsulinism, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.
The company's management team will be available for one-on-one meetings with investors during the conference. Interested investors should coordinate with their BTIG representatives to schedule meetings.
Rezolute (NASDAQ:RZLT), a late-stage rare disease company, will present baseline data from its fully enrolled Phase 3 sunRIZE study of ersodetug for congenital hyperinsulinism at ENDO 2025. The presentation, scheduled for July 14, 2025, will focus on patient demographics and characteristics from the trial.
The company's Chief Medical Officer highlighted that the presentation will provide insights into the study population and its comparability to the Phase 2 RIZE study. With enrollment complete, topline data is expected in December 2025, marking progress toward a potential new treatment option for patients with limited alternatives.